增加成本效益分析并不能提高可负担性。
Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability.
机构信息
Premera Blue Cross, Mountlake Terrace, Washington.
出版信息
J Manag Care Spec Pharm. 2020 Apr;26(4):407-408. doi: 10.18553/jmcp.2020.26.4.407.
Abstract
No outside funding contributed to this article. The authors are employed by Premera Blue Cross and have nothing to disclose.
摘要
本文无外部资金支持。作者为 Premera Blue Cross 员工，无利益披露。
相似文献
1
Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability.增加成本效益分析并不能提高可负担性。
J Manag Care Spec Pharm. 2020 Apr;26(4):407-408. doi: 10.18553/jmcp.2020.26.4.407.
2
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.治疗美国复发性/难治性多发性骨髓瘤药物的成本效益分析。
J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. doi: 10.18553/jmcp.2018.24.1.29.
3
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.口服司美格鲁肽添加到当前抗高血糖治疗方案用于 2 型糖尿病的成本效果分析。
J Manag Care Spec Pharm. 2021 Apr;27(4):455-468. doi: 10.18553/jmcp.2021.27.4.455.
4
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.评估赛来昔布单抗单药治疗中重度活跃类风湿关节炎成人患者的价值：成本效果分析。
J Manag Care Spec Pharm. 2019 Jan;25(1):80-87. doi: 10.18553/jmcp.2019.25.1.080.
5
The Effectiveness and Value of Treatments for Spinal Muscular Atrophy.脊髓性肌萎缩症治疗的有效性和价值。
J Manag Care Spec Pharm. 2019 Dec;25(12):1300-1306. doi: 10.18553/jmcp.2019.25.12.1300.
6
The effectiveness and value of novel treatments for cystic fibrosis.新型囊性纤维化治疗方法的效果和价值。
J Manag Care Spec Pharm. 2021 Feb;27(2):276-280. doi: 10.18553/jmcp.2021.27.2.276.
7
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.中重度斑块状银屑病靶向药物治疗的成本效益分析。
J Manag Care Spec Pharm. 2018 Dec;24(12):1210-1217. doi: 10.18553/jmcp.2018.24.12.1210.
8
Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?我们能否为美国医疗保健系统中的价值评估开发可持续和可共享的成本效益模型？
J Manag Care Spec Pharm. 2019 May;25(5):521-524. doi: 10.18553/jmcp.2019.25.5.521.
9
The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.作者回复：重新定义复发/难治性多发性骨髓瘤治疗的价值。
J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. doi: 10.18553/jmcp.2018.24.7.712.
10
The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.派司奴单抗和依多萨林治疗遗传性转甲状腺素蛋白淀粉样变性的效果和价值。
J Manag Care Spec Pharm. 2019 Jan;25(1):10-15. doi: 10.18553/jmcp.2019.25.1.010.
引用本文的文献
1
A review of HTA guidelines on societal and novel value elements.关于 HTA 指南中社会和新颖价值要素的综述。
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
2
Real-world evidence for option value in metastatic melanoma.转移性黑色素瘤的实际证据中的期权价值。
J Manag Care Spec Pharm. 2021 Nov;27(11):1546-1555. doi: 10.18553/jmcp.2021.21192. Epub 2021 Aug 25.
3
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.增强不确定性下的成本效益分析：对价值评估的影响——理论依据与实证支持
J Manag Care Spec Pharm. 2020 Apr;26(4):400-406. doi: 10.18553/jmcp.2020.26.4.400.
本文引用的文献
1
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.增强不确定性下的成本效益分析：对价值评估的影响——理论依据与实证支持
J Manag Care Spec Pharm. 2020 Apr;26(4):400-406. doi: 10.18553/jmcp.2020.26.4.400.
2
Affordability of Health Care: A Global Crisis.医疗保健的可负担性：一场全球危机。
Value Health. 2018 Mar;21(3):280-282. doi: 10.1016/j.jval.2018.01.001.
3
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts.解决“性价比高但负担不起”的悖论：估算非边际预算影响的健康机会成本。
Value Health. 2018 Mar;21(3):266-275. doi: 10.1016/j.jval.2017.10.006. Epub 2018 Jan 4.
4
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会（ISPOR）特别工作组报告的总结与建议[7]
Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.
5
Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.资助新型高成本抗癌药物的陈述性偏好与显示性偏好：对来自患者、公众和支付方证据的批判性综述
Patient. 2016 Jun;9(3):201-22. doi: 10.1007/s40271-015-0139-7.
6
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.英国国家卫生与临床优化研究所成本效益阈值的估计方法。
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
Zotero 插件